

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number
WO 2006/063999 A1

(51) International Patent Classification:

C07C 235/78 (2006.01) **C07D 263/32** (2006.01)
C07C 311/51 (2006.01) **C07D 213/75** (2006.01)
C07C 233/11 (2006.01) **C07D 213/74** (2006.01)
C07C 231/16 (2006.01) **A61P 29/00** (2006.01)
C07D 307/46 (2006.01) **A61K 31/16** (2006.01)
C07D 307/80 (2006.01) **A61K 31/18** (2006.01)
C07D 277/30 (2006.01)

(21) International Application Number:

PCT/EP2005/056742

(22) International Filing Date:

13 December 2005 (13.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

04029684.0 15 December 2004 (15.12.2004) EP

(71) Applicant (for all designated States except US): **DOMPÉ S.p.A.** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALLEGRETTI, Marcello** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT). **BERTINI, Riccardo** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT). **BECCARI, Andrea** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT). **MORICONI, Alessio** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT). **ARAMINI, Andrea** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT). **BIZZARRI, Cinzia** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT). **COLOTTA, Francesco** [IT/IT]; Dompé S.p.A., Via Campo di Pile, I-67100 L'Aquila (IT).

(74) Agent: **PIERACCIOLI, Daniele**; Dompé S.p.A., Via San Martino, 12, I-20122 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

(57) Abstract: The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.



WO 2006/063999 A1